From FDA labels and ClinicalTrials.gov

Do GLP-1s help Alzheimer's or dementia?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

No current GLP-1 label lists Alzheimer's and dementia as an approved use, so prescribing one for it would be off-label. evoke and evoke+ (Semaglutide tablets): Over 104 weeks, decline on the CDR-SB scale was 2.3 and 2.2 points on semaglutide against 2.3 and 2.1 on placebo. The authors conclude it was not efficacious in slowing early Alzheimer's disease. Lancet, 2026 (pubmed.ncbi.nlm.nih.gov/41865758). ClinicalTrials.gov lists 15 trials of these medicines on it: 3 with posted results and 3 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 6, 2026.

Published results

What the largest trials on Alzheimer's and dementia found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

evoke and evoke+

Semaglutide tablets · 3,808 people · No clear benefit · Placebo-controlled randomized trial

Over 104 weeks, decline on the CDR-SB scale was 2.3 and 2.2 points on semaglutide against 2.3 and 2.1 on placebo. The authors conclude it was not efficacious in slowing early Alzheimer's disease.

Lancet, 2026 (pubmed.ncbi.nlm.nih.gov/41865758)

The registry

Trials on Alzheimer's and dementia, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Semaglutide922
Liraglutide400
Exenatide110
Mazdutide101
Posted results

What trials on Alzheimer's and dementia reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
NCT05891496A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's DiseaseSemaglutidePhase 323Change in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF]) (Differentially expressed genes), Baseline (week 0), week 12. Semaglutide: 41.25; Placebo: 21.00.
NCT01255163A Pilot Clinical Trial of Exendin-4 in Alzheimer's DiseaseExenatidePhase 257Number of Participants With Incidence of Nausea (Participants), 18 months. Exendin-4: 5; Placebo: 0.
NCT05768945Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 InhibitorsSemaglutideNot phased742,670Time to Dementia Onset (Incidence rate per 1000 person year), Median follow up times: 1) 98 days (exp), 134 days (ref) 2) 118 days (exp), 132 days (ref) 3) 90 days (exp), 308 days (ref) 4) 99 days (exp), 135 days (ref), Analysis 1. Semaglutide: 4.40; DPP4 Inhibitors: 6.06.
Recruiting now

Trials on Alzheimer's and dementia taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study) (clinicaltrials.gov/study/NCT07083154)MazdutidePhase 3Aug 1, 2029
COMMETS- Combination MCI Metabolic Syndrome (clinicaltrials.gov/study/NCT06072963)SemaglutidePhase 2Dec 1, 2028
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease (clinicaltrials.gov/study/NCT07651319)SemaglutidePhase 1/2Dec 2029
From PubMed

Newest papers on GLP-1s and Alzheimer's and dementia

  • SGLT-2 Inhibitors versus GLP-1 Receptor Agonists for Dementia and Depression in Type 2 Diabetes Mellitus: A Meta-Analysis (pubmed.ncbi.nlm.nih.gov/42997476)

    Meta-analysis · Diabetes Metab Syndr Obes · Nov 2, 2026 · Pan R et al.

  • Impact of GLP-1 Receptor Agonists on Cognitive Performance in Adults at Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (pubmed.ncbi.nlm.nih.gov/42942883)

    Meta-analysis · Nutrients · Oct 9, 2026 · Abbatecola AM et al.

  • The Efficacy of Glucagon-like Peptide-1 Receptor Agonists on Different Cognitive Domains: A Meta-analysis of Randomized Controlled Trials (pubmed.ncbi.nlm.nih.gov/42163663)

    Meta-analysis · Curr Neuropharmacol · May 15, 2026 · Xu H et al.

  • Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial (pubmed.ncbi.nlm.nih.gov/41098140)

    Randomized trial · Clin Infect Dis · May 1, 2026 · Atieh O et al. · cited by 6

  • The Role of Antidiabetic Therapies in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review of Metformin, Pioglitazone, and GLP-1 Receptor Agonists (pubmed.ncbi.nlm.nih.gov/42123553)

    Systematic review · Int J Mol Sci · Apr 29, 2026 · Mahoon DA et al.

  • Effects of GLP-1 receptor agonists on vascular dementia: a systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/41619622)

    Meta-analysis · J Diabetes Complications · Jan 26, 2026 · Stefanou MI et al. · cited by 4

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Questions

GLP-1s and Alzheimer's and dementia: common questions

What did the largest trial on Alzheimer's and dementia find?

evoke and evoke+ (Semaglutide tablets, 3,808 people): Over 104 weeks, decline on the CDR-SB scale was 2.3 and 2.2 points on semaglutide against 2.3 and 2.1 on placebo. The authors conclude it was not efficacious in slowing early Alzheimer's disease.

Is any GLP-1 FDA approved for Alzheimer's and dementia?

Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.

Which GLP-1 has been studied most for Alzheimer's and dementia?

Semaglutide, with 9 registered trials on it, then Liraglutide with 4. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for Alzheimer's and dementia?

3 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.